The application of adrenomedullin precursor midbody peptide combined with serum calcitoninogen in the diagnosis and treatment of sepsis
Objective To analyze the application value of adrenomedullin precursor mid-peptide(MR-proADM)combined with calcitoninogen(PCT)test in the diagnosis and treatment of sepsis.Methods Forty-five sepsis patients admitted from January 2020 to June 2023 were selected as the sepsis group,and 43 healthy physical examiners were selected as the control group during the same period.Serum MR-proADM and PCT levels were measured within 24 h of admission for all those enrolled,and the sepsis group was divided into shock group(20 cases)and non-shock group(25 cases)according to whether they were shock sepsis,and into death group(5 cases)and survival group(40 cases)according to different prognosis.The MR-proADM and PCT levels in the control group were compared with those in the sepsis group,and the MR-proADM and PCT levels in each subgroup were also compared.The predictive value of MR-proADM and PCT indexes single test and combined test for sepsis were analyzed.Results MR-proADM and PCT levels were higher in the sepsis group compared with the control group(t=83.306,35.745,P<0.05).MR-proADM and PCT levels were higher in the shock group compared with the non-shock group(t=24.867,2.149,P<0.05).MR-proADM and PCT levels were higher in the death group compared with the survival group(t= 15.458,2.174,P<0.05).The area under the ROC curve(AUC)of the combined assay for predicting sepsis was higher than The area under the ROC curve(AUC)of the combined assay for predicting sepsis was higher than that of the MR-proADM and PCT single assay(P<0.05).Conclusion MR-proADM combined with PCT assay for sepsis diagnosis and treatment can provide a reliable basis for disease diagnosis and treatment,and can be used to assess prognosis.
CalcitoninogenSepsisCombined assayAdrenomedullin precursor intermediate peptideDiagnostic value
NETL
NSTL
万方数据
